Brief: Mineralys Therapeutics Announces First Subject Dosed In Launch-Htn In Trial Of Lorundrostat For Treatment Of Hypertension
21/12/2023 22:21
Dec 21 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS ANNOUNCES FIRST SUBJECT DOSED IN
LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE
TREATMENT OF HYPERTENSION
* MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM
CONFIRMATORY
LAUNCH-HTN TRIAL EXPECTED IN 2H 2025
* MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM ONGOING
ADVANCE-HTN PIVOTAL TRIAL EXPECTED IN 2H 2024
Source text for Eikon: ID:nGNX2MBDvh
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway